…of diabetes and cardiovascular disease than total adiposity alone. The waist circumference associated with risk varies among populations, reflecting differences in fat distribution and ethnicity…

…and Mechanisms Monoclonal Antibodies Evolocumab and alirocumab are fully human monoclonal antibodies that bind circulating PCSK9 and prevent its interaction with the hepatic LDL receptor…

…disorders Acute infection Renal or hepatic impairment Hypothyroidism Vitamin D deficiency Concomitant interacting medications The SLCO1B1 rs4149056 polymorphism is associated with higher statin concentrations and…

…and formulary availability; check what applies where you work. They assume normal renal and hepatic function, a non pregnant adult of normal weight, and individual…

…hyperbolic. In people with a low muscle mass — the elderly, the undernourished, amputees, patients with hepatic cirrhosis — creatinine based eGFR substantially overestimates renal function. Staging…

…and incompletely absorbed after oral administration, with systemic bioavailability ranging from 25% to 65% and minimal hepatic first pass extraction. Following a single oral dose…

…of cholesterol delivered to the liver. The resulting hepatic response includes increased expression of low density lipoprotein receptors (LDLRs), which enhances removal of circulating LDL…

…availability of hepatic LDL receptors. Rare biallelic variants in LDLRAP1, which impair LDL receptor endocytosis and produce an FH like phenotype. Individuals with a single…

…intensive approach: treatment should begin immediately, with combination therapy added when necessary to achieve the recommended LDL C target. Inclisiran: pharmacology and lipid effects Inclisiran…

…and pathophysiology Lipid lowering therapy is a central component of cardiovascular prevention, particularly in patients with established atherosclerotic cardiovascular disease (ASCVD), chronic coronary syndrome (CCS)…